Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report.

MLA

Lin, Andrea, et al. “Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report.” Diabetes, 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1391595821&authtype=sso&custid=ns315887.

APA

Lin, A., Lin, A., Mack, J. A., Bruggeman, B., Jacobsen, L. M., Posgai, A. L., Wasserfall, C. H., Brusko, T. M., Atkinson, M. A., Gitelman, S. E., Gottlieb, P. A., Gurka, M. J., Mathews, C. E., Schatz, D. A., & Haller, M. J. (2021). Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report. Diabetes.

Chicago

Lin, Andrea, Andrea Lin, Jasmine A Mack, Brittany Bruggeman, Laura M Jacobsen, Amanda L Posgai, Clive H Wasserfall, et al. 2021. “Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report.” Diabetes. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1391595821&authtype=sso&custid=ns315887.